Quest Diagnostics (DGX) subsidiary, Haystack Oncology, partners on the use of its MRD technology.…
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 1.73% and 0.50%, respectively, for the quarter ended June 2024. Do…
…
Quest Diagnostics (DGX) is likely to have maintained its robust base business performance in the second quarter of 2024. However,…
…
The Global Precision Diagnostics Market Size was Valued at USD 74.98 Billion in 2023 and the Worldwide Precision Diagnostics Market…
By integrating LifeLabs into its operations, Quest Diagnostics (DGX) aims to enhance the accessibility and quality of diagnostic services for…
The Global PCOS Diagnostic Market Size was Valued at USD 3.68 Billion in 2023 and the Worldwide PCOS Diagnostic Market…
Strength in the core business bodes well for Quest Diagnostics (DGX). However, mounting debt levels and reduced COVID-19 testing revenues…
DJ PTA-News: Small- & MicroCap Investment: KI als Wachstumsmotor: CrowdStrike, Adcore, Quest Diagnostics Unternehmensmitteilung für den Kapitalmarkt Frankfurt (pta/23.06.2024/10:00) -…
In Physician Lab Services, Quest Diagnostics (DGX) is benefiting from the broad-based return to care, overall market growth and share…
Quest Diagnostics (DGX) completes the acquisition of PathAI Diagnostics, accelerating the adoption of AI and digital pathology to improve cancer…
…
…
Wenig Kursbewegung aktuell bei der Aktie von Quest Diagnostics . Der jüngste Kurs betrug 136,84 US-Dollar. Die Wertschätzung der Börsenteilnehmer…
…
Quest Diagnostics (DGX) pathology laboratories nationwide are set to get a boost with PathAIs AISight digital pathology image management system.…
Quest Diagnostics (DGX) latest transaction combines its oncology expertise and scale with PathAIs AI and digital pathology innovations.…
Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.…
CODE Das Wertpapier notiert aktuell bei 128,30 US-Dollar. Kaum auffällig ist derzeit an der Börse der Kurs von Quest Diagnostics.…
Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics (DGX) base business performance in the first quarter…
Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal…
…
Quest Diagnostics (DGX) faces intense competition, primarily from LabCorp as well as other commercial laboratories and hospitals.…
Quest Diagnostics (DGX) debuts the MelaNodal Predict test in collaboration with SkylineDx.…
Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.…
Strength of the base business bodes well for Quest Diagnostics (DGX).…
Earnings call: Quest Diagnostics sees robust growth and AI investment…
Im Minus liegt derzeit die Aktie von Quest Diagnostics . Das Papier kostete zuletzt 126,16 US-Dollar. Im US-amerikanischen Wertpapierhandel hat…
…
Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the fourth quarter of 2023.…
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 0.47% and 1.80%, respectively, for the quarter ended December 2023. Do…
Quest Diagnostics (DGX) subsidiary Haystack Oncology collaborates with TriSalus Life Sciences to improve therapeutic options for aggressive forms of cancer.…
Quest Diagnostics (DGX) partners with Fitbit to study the potential of wearable devices to improve metabolic health.…
Prestige Consumer Health (PBH), Quest Diagnostics (DGX) and Hologic (HOLX) are currently at discounted zone that are expected to provide…
Quest Diagnostics (DGX) fourth-quarter 2023 results are likely to reflect the robust strength of its base business.…
Quest Diagnostics (DGX) new partnership is likely to leverage its oncology expertise and national scale.…
Quest Diagnostics (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.…
Investors are optimistic about Quest Diagnostics (DGX) on strength in base business and strategic collaborations.…
Quest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic.…
Quest Diagnostics (DGX) wholly owned subsidiary, Haystack Oncology, partners with the Rutgers Cancer Institute of New Jersey.…
Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.…
Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business.…
Quest Diagnostics (DGX) will supply next-generation sequencing and enhanced RNA extraction services for Sciphers PrismRA test through a new collaboration.…
Quest Diagnostics (DGX) latest partnership will increase the likelihood that Americans will eventually have an easy, reliable and accessible way…
Der amerikanische Medizintechniker Quest Diagnostics Inc. (ISIN: US74834L1008, NYSE: DGX) zahlt am 31. Januar 2024 eine vierteljährliche Dividende in Höhe…
Quest Diagnostics (DGX) can offer patients and physicians a seamless connection to Quest Diagnostics laboratory testing with the launch of…
…
Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Asia Cervical Cancer Screening Market, Size, Forecast 2023-2028, Industry Trends,…
Anzeige / WerbungQuest Diagnostics setzt Maßstäbe im bärischen BörsenumfeldWährend die Aktienmärkte aktuell allgemein auf Tauchstation gehen und ihrem Bärenmarkt folgen,…